Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Bergmark, Brian A., Marston, Nicholas A., Prohaska, Thomas A., Alexander, Veronica J., Zimerman, André, Moura, Filipe A., Murphy, Sabina A., Goodrich, Erica L., Zhang, Shuanglu, Gaudet, Daniel, Karwatowska-Prokopczuk, Ewa, Tsimikas, Sotirios, Giugliano, Robert P., Sabatine, Marc S.·2024·New England Journal of Medicine
DOI 10.1056/nejmoa2402309

Cited by (207)

Items 201–207 of 207

  1. A Look At Non-Statin Lipid-Lowering Pharmacological Therapy
    Alexey Vedernikov, Межонов Евгений Михайлович, S.A. Vedernikova, Yu. A. Vyalkina · 2026 · The Russian Archives of Internal Medicine
  2. Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review and evidence map of randomised controlled trials
    Eric A. Apaydin, Jessica V. Richard, Skye Adell Miner, Molly Waymouth, Derek Roberts, Jerry Vockley, Andrea S. Richardson · 2026 · Open Heart
  3. siRNA therapeutics: from hepatic delivery to extrahepatic targeting
    Nan Wang, Lingxi Meng, Jia-Xin Shi, Matthias Bartneck · 2026 · Expert Opinion on Drug Delivery
  4. Mixed-Backbone Oligonucleotides for Therapeutics: The Way of the Future
    Shalini Gupta · 2026 · JACS Au
  5. Targeting Apolipoprotein C-III in Hypertriglyceridemia: Implications for Pancreatitis and Cardiovascular risk
    André Zimerman, Nicholas Marston · 2026 · Current Atherosclerosis Reports
  6. Atherosclerosis: From Pathogenesis to Therapeutic Interventions
    Enge Zhou, Chenxi Zhan, Yuting Li, Yi Zeng, Renfei Luo, Xin Ouyang, Shixing Liu, Renqiang Yang, Nianlong Yan, Long Jiang · 2026 · MedComm
  7. Choline fenofibrate add-on to statins in persistent hypertriglyceridemia: efficacy, apoB-containing lipoprotein remodeling, and renal function
    Byung Jin Kim, Hyeon Ju Jeong, Eun Seok Kang, Min-Woong Kim, Sang-Hyun Kim, Yong-Hyun Kim, Ki Hong Lee, Geu-Ru Hong, Young Sup Byun, Hoyoun Won et al. · 2026 · Atherosclerosis Plus